Concert Pharmaceuticals (CNCE) Upgraded at BidaskClub

BidaskClub upgraded shares of Concert Pharmaceuticals (NASDAQ:CNCE) from a buy rating to a strong-buy rating in a research report report published on Saturday.

Several other brokerages also recently commented on CNCE. Stifel Nicolaus restated a buy rating and issued a $30.00 target price on shares of Concert Pharmaceuticals in a research note on Sunday, October 22nd. HC Wainwright restated a buy rating and issued a $20.00 target price on shares of Concert Pharmaceuticals in a research note on Monday, September 18th. Zacks Investment Research cut shares of Concert Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, October 10th. Mizuho initiated coverage on shares of Concert Pharmaceuticals in a research report on Thursday, October 26th. They issued a buy rating and a $23.00 price target on the stock. Finally, TheStreet raised shares of Concert Pharmaceuticals from a d rating to a c+ rating in a research report on Wednesday, November 29th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Concert Pharmaceuticals has a consensus rating of Buy and a consensus target price of $23.00.

Shares of Concert Pharmaceuticals (NASDAQ:CNCE) opened at $25.21 on Friday. Concert Pharmaceuticals has a 12 month low of $7.11 and a 12 month high of $26.37.

In other Concert Pharmaceuticals news, Director Ronald W. Barrett sold 14,156 shares of Concert Pharmaceuticals stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $24.70, for a total transaction of $349,653.20. Following the transaction, the director now owns 3,539 shares of the company’s stock, valued at approximately $87,413.30. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ryan Lynch sold 3,500 shares of Concert Pharmaceuticals stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $14.51, for a total transaction of $50,785.00. Following the transaction, the insider now directly owns 9,500 shares in the company, valued at approximately $137,845. The disclosure for this sale can be found here. 10.10% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its position in shares of Concert Pharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after buying an additional 287 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Concert Pharmaceuticals by 0.6% during the 1st quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock worth $2,435,000 after buying an additional 838 shares in the last quarter. Alps Advisors Inc. lifted its position in shares of Concert Pharmaceuticals by 6.3% during the 2nd quarter. Alps Advisors Inc. now owns 20,362 shares of the biotechnology company’s stock worth $284,000 after buying an additional 1,200 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Concert Pharmaceuticals by 8.0% during the 2nd quarter. Rhumbline Advisers now owns 20,253 shares of the biotechnology company’s stock worth $283,000 after buying an additional 1,500 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Concert Pharmaceuticals by 1.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 125,996 shares of the biotechnology company’s stock worth $1,757,000 after buying an additional 1,852 shares in the last quarter. 65.36% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was posted by Week Herald and is the property of of Week Herald. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://weekherald.com/2017/12/12/concert-pharmaceuticals-cnce-upgraded-at-bidaskclub.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply